These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
225 related articles for article (PubMed ID: 17487399)
1. VEGF transcription and mRNA stability are altered by WT1 not DDS(R384W) expression in LNCaP cells. Cash J; Korchnak A; Gorman J; Tandon Y; Fraizer G Oncol Rep; 2007 Jun; 17(6):1413-9. PubMed ID: 17487399 [TBL] [Abstract][Full Text] [Related]
2. Transcriptional regulation of the androgen signaling pathway by the Wilms' tumor suppressor gene WT1. Zaia A; Fraizer GC; Piantanelli L; Saunders GF Anticancer Res; 2001; 21(1A):1-10. PubMed ID: 11299720 [TBL] [Abstract][Full Text] [Related]
3. Vascular endothelial growth factor (VEGF) is suppressed in WT1-transfected LNCaP cells. Graham K; Li W; Williams BR; Fraizer G Gene Expr; 2006; 13(1):1-14. PubMed ID: 16572586 [TBL] [Abstract][Full Text] [Related]
4. Impaired glomerular maturation and lack of VEGF165b in Denys-Drash syndrome. Schumacher VA; Jeruschke S; Eitner F; Becker JU; Pitschke G; Ince Y; Miner JH; Leuschner I; Engers R; Everding AS; Bulla M; Royer-Pokora B J Am Soc Nephrol; 2007 Mar; 18(3):719-29. PubMed ID: 17267748 [TBL] [Abstract][Full Text] [Related]
5. Suppression of prostate tumor cell growth in vivo by WT1, the Wilms' tumor suppressor gene. Fraizer G; Leahy R; Priyadarshini S; Graham K; Delacerda J; Diaz M Int J Oncol; 2004 Mar; 24(3):461-71. PubMed ID: 14767530 [TBL] [Abstract][Full Text] [Related]
6. Overexpression of Id-1 in prostate cancer cells promotes angiogenesis through the activation of vascular endothelial growth factor (VEGF). Ling MT; Lau TC; Zhou C; Chua CW; Kwok WK; Wang Q; Wang X; Wong YC Carcinogenesis; 2005 Oct; 26(10):1668-76. PubMed ID: 15905202 [TBL] [Abstract][Full Text] [Related]
7. Murine Denys-Drash syndrome: evidence of podocyte de-differentiation and systemic mediation of glomerulosclerosis. Patek CE; Fleming S; Miles CG; Bellamy CO; Ladomery M; Spraggon L; Mullins J; Hastie ND; Hooper ML Hum Mol Genet; 2003 Sep; 12(18):2379-94. PubMed ID: 12915483 [TBL] [Abstract][Full Text] [Related]
8. Differential expression of angiopoietin-2 and vascular endothelial growth factor in androgen-independent prostate cancer models. Tesan T; Gustavsson H; Welén K; Damber JE BJU Int; 2008 Sep; 102(8):1034-9. PubMed ID: 18489523 [TBL] [Abstract][Full Text] [Related]
9. Analysis of WT1 target gene expression in stably transfected cell lines. Thäte C; Englert C; Gessler M Oncogene; 1998 Sep; 17(10):1287-94. PubMed ID: 9771972 [TBL] [Abstract][Full Text] [Related]
10. Regulation of vascular endothelial growth factor, VEGF, gene promoter by the tumor suppressor, WT1. Hanson J; Gorman J; Reese J; Fraizer G Front Biosci; 2007 Jan; 12():2279-90. PubMed ID: 17127464 [TBL] [Abstract][Full Text] [Related]
11. A SNP in the flt-1 promoter integrates the VEGF system into the p53 transcriptional network. Menendez D; Krysiak O; Inga A; Krysiak B; Resnick MA; Schönfelder G Proc Natl Acad Sci U S A; 2006 Jan; 103(5):1406-11. PubMed ID: 16432214 [TBL] [Abstract][Full Text] [Related]
12. An autocrine loop for vascular endothelial growth factor is established in prostate cancer cells generated after prolonged treatment with interleukin 6. Steiner H; Berger AP; Godoy-Tundidor S; Bjartell A; Lilja H; Bartsch G; Hobisch A; Culig Z Eur J Cancer; 2004 May; 40(7):1066-72. PubMed ID: 15093584 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of Src kinase activity by Ad-mda7 suppresses vascular endothelial growth factor expression in prostate carcinoma cells. Inoue S; Branch CD; Gallick GE; Chada S; Ramesh R Mol Ther; 2005 Oct; 12(4):707-15. PubMed ID: 16054437 [TBL] [Abstract][Full Text] [Related]
14. JunD mediates androgen-induced oxidative stress in androgen dependent LNCaP human prostate cancer cells. Mehraein-Ghomi F; Lee E; Church DR; Thompson TA; Basu HS; Wilding G Prostate; 2008 Jun; 68(9):924-34. PubMed ID: 18386285 [TBL] [Abstract][Full Text] [Related]
15. Role of Wilms tumor 1 (WT1) in the transcriptional regulation of the Mullerian-inhibiting substance promoter. Hossain A; Saunders GF Biol Reprod; 2003 Dec; 69(6):1808-14. PubMed ID: 12855602 [TBL] [Abstract][Full Text] [Related]
16. Estrogen regulation of vascular endothelial growth factor in breast cancer in vitro and in vivo: the role of estrogen receptor alpha and c-Myc. Dadiani M; Seger D; Kreizman T; Badikhi D; Margalit R; Eilam R; Degani H Endocr Relat Cancer; 2009 Sep; 16(3):819-34. PubMed ID: 19398483 [TBL] [Abstract][Full Text] [Related]
17. Profiling of gene expression changes caused by p53 gain-of-function mutant alleles in prostate cancer cells. Tepper CG; Gregg JP; Shi XB; Vinall RL; Baron CA; Ryan PE; Desprez PY; Kung HJ; deVere White RW Prostate; 2005 Dec; 65(4):375-89. PubMed ID: 16037992 [TBL] [Abstract][Full Text] [Related]
18. Microarray analysis reveals potential target genes of NF-kappaB2/p52 in LNCaP prostate cancer cells. Nadiminty N; Dutt S; Tepper C; Gao AC Prostate; 2010 Feb; 70(3):276-87. PubMed ID: 19827050 [TBL] [Abstract][Full Text] [Related]
19. Transcriptional regulation of the homeobox gene NKX3.1 by all-trans retinoic acid in prostate cancer cells. Thomas MA; Hodgson MC; Loermans SD; Hooper J; Endersby R; Bentel JM J Cell Biochem; 2006 Dec; 99(5):1409-19. PubMed ID: 16817226 [TBL] [Abstract][Full Text] [Related]
20. Androgens repress the expression of the angiogenesis inhibitor thrombospondin-1 in normal and neoplastic prostate. Colombel M; Filleur S; Fournier P; Merle C; Guglielmi J; Courtin A; Degeorges A; Serre CM; Bouvier R; Clézardin P; Cabon F Cancer Res; 2005 Jan; 65(1):300-8. PubMed ID: 15665307 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]